Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells

Authors Kim DH, Jeong Y, Chung C, Kim CH, Kwak TW, Lee HM, Kang DH

Received 31 January 2013

Accepted for publication 18 March 2013

Published 30 April 2013 Volume 2013:8(1) Pages 1697—1711


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Do Hyung Kim,1,2,* Young-Il Jeong,1,* Chung-Wook Chung,1 Cy Hyun Kim,1,2 Tae Won Kwak,1 Hye Myeong Lee,1 Dae Hwan Kang1,2

National Research and Development Center for Hepatobiliary Cancer, Pusan National University Yangsan Hospital, 2School of Medicine, Pusan National University, Yangsan, Gyeongsangnam-do, South Korea

*These authors equally contributed to this work.

Background: Cholangiocarcinoma is a malignant tumor arising from the epithelium of the bile ducts. In this study, we prepared sorafenib-loaded biliary stents for potential application as drug-delivery systems for localized treatment of extrahepatic cholangiocarcinoma.
Methods: A sorafenib-coated metal stent was prepared using an electrospray system with the aid of poly(ε-caprolactone) (PCL), and then its anticancer activity was investigated using human cholangiocellular carcinoma (HuCC)-T1 cells in vitro and a mouse tumor xenograft model in vivo. Anticancer activity of sorafenib against HuCC-T1 cells was evaluated by the proliferation test, matrix metalloproteinase (MMP) activity, cancer cell invasion, and angiogenesis assay in vitro and in vivo.
Results: The drug-release study showed that the increased drug content on the PCL film induced a faster drug-release rate. The growth of cancer cells on the sorafenib-loaded PCL film surfaces decreased in a dose-dependent manner. MMP-2 expression of HuCC-T1 cells gradually decreased according to sorafenib concentration. Furthermore, cancer cell invasion and tube formation of human umbilical vein endothelial cells significantly decreased at sorafenib concentrations higher than 10 mM. In the mouse tumor xenograft model with HuCC-T1 cells, sorafenib-eluting PCL films significantly inhibited the growth of tumor mass and induced apoptosis of tumor cells. Various molecular signals, such as B-cell lymphoma (Bcl)-2, Bcl-2-associated death promoter, Bcl-x, caspase-3, cleaved caspase-3, Fas, signal transducer and activator of transcription 5, extracellular signal-regulated kinases, MMP-9 and pan-janus kinase/stress-activated protein kinase 1, indicated that apoptosis, inhibition of growth and invasion was cleared on sorafenib-eluting PCL films.
Conclusion: These sorafenib-loaded PCL films are effective in inhibiting angiogenesis, proliferation and invasion of cancer cells. We suggest that sorafenib-loaded PCL film is a promising candidate for the local treatment of cholangiocarcinoma.

Keywords: sorafenib, polycaprolactone, biliary stent, human cholangiocarcinoma cells, angiogenesis

A Letter the the Editor has been received and published for this article.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?

Tomuleasa C, Cucuianu A, Aldea M, Berindan-Neagoe I

International Journal of Nanomedicine 2013, 8:4043-4044

Published Date: 23 October 2013

Process optimization and evaluation of novel baicalin solid nanocrystals

Yue PF, Li Y, Wan J, Wang Y, Yang M, Zhu WF, Wang CH, Yuan HL

International Journal of Nanomedicine 2013, 8:2961-2973

Published Date: 9 August 2013

Barium titanate core – gold shell nanoparticles for hyperthermia treatments

FarrokhTakin E, Ciofani G, Puleo GL, de Vito G, Filippeschi C, Mazzolai B, Piazza V, Mattoli V

International Journal of Nanomedicine 2013, 8:2319-2331

Published Date: 28 June 2013

Nanodiscs as a therapeutic delivery agent: inhibition of respiratory syncytial virus infection in the lung

Numata M, Grinkova YV, Mitchell JR, Chu HW, Sligar SG, Voelker DR

International Journal of Nanomedicine 2013, 8:1417-1427

Published Date: 15 April 2013

Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138–  CD34– tumor stem-like cells in multiple myeloma-bearing mice

Yang C, Wang J, Chen D, Chen J, Xiong F, Zhang H, Zhang Y, Gu N, Dou J

International Journal of Nanomedicine 2013, 8:1439-1449

Published Date: 12 April 2013

Application of liposomes in drug development – focus on gastroenterological targets

Zhang JX, Wang K, Mao ZF, Fan X, Jiang DL, Chen M, Cui L, Sun K, Dang SC

International Journal of Nanomedicine 2013, 8:1325-1334

Published Date: 8 April 2013

Degradation and osteogenic potential of a novel poly(lactic acid)/nano-sized β-tricalcium phosphate scaffold

Cao L, Duan PG, Wang HR, Li XL, Yuan FL, Fan ZY, Li SM, Dong J

International Journal of Nanomedicine 2012, 7:5881-5888

Published Date: 28 November 2012

Portable microfluidic chip for detection of Escherichia coli in produce and blood

Wang S, Inci F, Chaunzwa TL, Ramanujam A, Vasudevan A, Subramanian S, Ip AC, Sridharan B, Gurkan UA, Demirci U

International Journal of Nanomedicine 2012, 7:2591-2600

Published Date: 29 May 2012